Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia
A novel niosomal delivery system was designed and investigated for the targeted delivery of daunorubicin (DNR) against acute myeloid leukemia (AML). Anti-CD123 antibodies conjugated to Mal-PEG2000-DSPE were incorporated into normal niosomes (NS) via a post insertion method to afford antibody-modifie...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-01-01
|
Series: | Drug Delivery |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/10717544.2017.1333170 |